AntriaBio

Investors

Press Releases

Feb 10, 2020 Rezolute Initiates Phase 2b Clinical Trial of Lead Candidate RZ358 in Congenital Hyperinsulinism
Jan 27, 2020 Rezolute to Present at BIO CEO & Investor Conference 2020
Dec 18, 2019 Rezolute, Inc. Announces Top-line Results from Phase 1 Trial Evaluating AB101 in Patients with Diabetes
Dec 2, 2019 Rezolute Management to Present at 2020 Biotech Showcase Conference
Nov 25, 2019 Rezolute Appoints Nektar Therapeutics COO & CFO to Its Board of Directors
Oct 11, 2019 Rezolute Management to Present at 2019 BIO Investor Forum Conference
Aug 5, 2019 Rezolute Management to Present at 2019 Canaccord Genuity Growth Conference
Jul 24, 2019 Rezolute Completes $45 Million Investment Round with Full Exercise of $20 Million Option
Jan 7, 2019 Rezolute Announces $25 Million Private Placement -- Potential Total Investment of $45 Million
May 16, 2018 Rezolute Announces Appointment of Keith Vendola as Chief Financial Officer

1
2
3
4
5
6
Next >>

Show All